Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
|Videos|March 13, 2017
Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
Author(s)Ursula Matulonis, M.D.
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Advertisement
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.
Advertisement
Related to this article
WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.
Advertisement
Advertisement
Trending on CURE
1
3 More Lung Cancer Breakthroughs From WCLC 2026
2
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
3
Myeloma Guidelines Call for Yearly Measurable Residual Disease Testing
4
The Service Dog Who Helped Me Keep Fighting
5